There have been significant advances in glucose lowering therapies in T2DM and their availability, thus offering a greater choice of therapies to people with diabetes with the potential for supporting safer fasting. Three new classes of therapy have been licensed for the treatment of T2DM in the United Kingdom (UK) in the past 10 years. The most recent class that has been introduced are the Sodium Glucose Co-Transporter 2 Inhibitors (SGLT2 inhibitors). There are six known members of the SGLT family to date. Canagliflozin (Invokana™), a once daily tablet, is one of a number of SGLT2 inhibitors that have been licensed within the UK. This medication is taken once daily orally (either 100 or 300mg). Phase III trials of this novel agent have reported reductions in HbA1c between 0.70 and 1.16%, body weight reduction between 1.8 and 3.7% and systolic blood pressure reduction between 1.6 and 6.6mmHg (millimetre of mercury) from baseline. Canagliflozin (Invokana™) has a low intrinsic propensity to cause hypoglycaemia. Importantly this drug is reported to be well-tolerated and has a good safety profile in patients with inadequately controlled T2DM as monotherapy or in combination with other glucose lowering therapy including sulphonylureas and metformin.